Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2491 to 2505 of 7686 results

  1. Olipudase alfa for treating Niemann-Pick disease types A and B [ID3913 ]

    In development [GID-HST10060] Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  2. Fosdenopterin for treating molybdenum cofactor deficiency type A [ID6264]

    In development [GID-HST10055] Expected publication date: 29 January 2025

    Highly specialised technologies guidance
    In development

  3. Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170]

    In development [GID-TA11106] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome

    In development [GID-DG10074] Expected publication date: 19 December 2024

    Diagnostics guidance
    In development

  5. Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]

    In development [GID-TA10165] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Spesolimab for treating generalised pustular psoriasis flares [ID3963]

    In development [GID-TA10871] Expected publication date: 19 March 2025

    Technology appraisal guidance
    In development

  7. Pembrolizumab with platinum-based chemotherapy then pembrolizumab maintenance for treating primary advanced or recurrent endometrial cancer ID6381

    In development [GID-TA11461] Expected publication date: 16 April 2025

    Technology appraisal guidance
    In development

  8. Triheptanoin for treating long-chain fatty acid oxidation disorders ID3891

    In development [GID-TA11473] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Somapacitan for treating growth failure associated with being small for gestational age, Noonan syndrome or idiopathic short height TSID 12070

    Awaiting development [GID-TA11641] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Pridopidine for treating Huntington's disease TSID 12052

    Awaiting development [GID-TA11637] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Govorestat for treating classic galactosemia in people 2 to 65 years TS ID 12071

    Awaiting development [GID-TA11634] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Sumatriptan–naproxen for treating migraine-related moderate to severe headache [TS ID 12055]

      Status ...

    Technology appraisal guidance
    Topic selection

  13. Ustekinumab for the treatment of moderately to severely active Crohn's disease in children [TS ID 11955]

      Status ...

    Technology appraisal guidance
    Topic selection

  14. Budesonide oral suspension for maintaining remission of eosinophilic oesophagitis in people 2 years and over ID6486

    Awaiting development [GID-TA11623] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis [TS ID 12050]

    Awaiting development [GID-TA11628] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development